

Date: 14.11.2024

To,
National Stock Exchange of India Limited
Exchange Plaza,
5th Floor, Plot No. C/1, G Block,
Bandra Kurla Complex Bandra (E),
Mumbai - 400051

Company Symbol - SUNREST

Dear Sir / Madam,

Sub: Outcome of Board Meeting - Financial Results for the Quarter and Half year ended 30th September, 2024.

Pursuant to the provisions of Regulation 30 and 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, we wish to inform you that a meeting of the Board of Directors of **SUNREST LIFESCIENCE LIMITED** was held today i.e. **November 14, 2024** commenced at **11.00 AM** and concluded at **3.00 PM**. The meeting inter alia transacted following business.

The board of directors has approved the following resolution.

1. Considered and approved Standalone Unaudited Financial Results of the company for the Quarter and half year ended **30th September, 2024** along with the Limited Review Report

Kindly take the above resolution on records.

Thanking You
Yours Faithfully,

For SUNREST LIFESCIENCE LIMITED

NISHI B SHAH
Compliance Officer & Company Secretary
Membership No: 60297

Sunrest Lifescience Limited

To,

Board of Directors

Sunrest Lifescience Limited

Ahmedabad

Report on the standalone audited financial results

Opinion

We have audited the accompanying standalone financial results of Sunrest Lifescience Limited [Formerly known as Sunrest Lifescience Private Limited] for the period of 6 months ended September 30, 2024, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended ('Listing Regulations').

In our Opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- a. Are presented in accordance with the requirements of Regulations 33 and 52 read with Regulation 63(2) of the Listing Regulations in this regard, and
- b. Gives a true and fair view in conformity with recognition and measurement principles laid down in applicable Accounting Standards prescribed under section 133 of Companies Act, 2013 (the "Act") read with Rule 7 of Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India, of the net profit and other financial information for the half year ended 30th September 2024 as well as the results for the year ended on 30th September, 2024.

Basis for opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's and Board of Director's Responsibility for the Standalone Annual Financials Results

These Standalone annual financial results have been prepared on the basis of the standalone annual financial statements. The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit /loss and other financial information in accordance with the Accounting Standards prescribed under



Section 133 of the Act read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 read with Regulation 63(2) of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error. In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results for the year ended September, 30 2024 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results. As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional scepticism throughout the audit.

We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material



uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards

Other Matters:

The standalone annual financial result includes the results for the full year ended 31st March 2024 which are audited by us.

For, Madhusudan C Mashruwala and Co.,

Chartered Accountants

FRN 105717W



Date: 14-11-2024

Place: Ahmedabad

Soham U Mashruwala

Partner

Mem no.137995

UDIN: 24137995BKCJRP9054



SUNREST LIFESCENCE LIMITED
 FF-41 AJAY TENAMENT-6 NEAR CANAL NEAR RITANAGAR BUS STAND VASTRAL ROAD Ahmedabad GJ 382415
 CIN: U74999GJ2017PLC099606
 BALANCE SHEET AS AT 30-09-2024

Particulars	Note	30/09/2024	31/03/2024
in ₹ Lacs			
EQUITY AND LIABILITIES			
Shareholders' funds			
Share capital	2.1	429.12	429.12
Reserves and surplus	2.2	1047.58	989.42
Money received against share warrants		-	-
		1476.70	1418.54
Share application money pending allotment		-	-
Non-current liabilities			
Long-term borrowings	2.3	322.03	346.18
Deferred tax liabilities (Net)		-	-
Other Long term liabilities	2.3A	34.00	-
		356.03	346.18
Current liabilities			
Short-term borrowings	2.3B	222.89	269.79
Trade payables			
Total outstanding dues of micro enterprises and small enterprises	2.4	421.88	30.76
Total outstanding dues of creditors other than micro enterprises and small enterprises		183.27	348.81
Other current liabilities	2.5	16.70	37.98
Short-term provisions	2.6	37.58	63.50
		882.31	750.83
TOTAL		2715.04	2515.55
ASSETS			
Non-current assets			
Property, Plant and Equipment and Intangible Assets			
Property, Plant and Equipment	2.7	3.36	25.37
Intangible assets		0.68	0.69
Capital work-in-progress		-	-
Intangible assets under development		-	-
		4.04	26.05
Non-current investments	2.7A	-	1.65
Deferred tax assets (net)	2.8	2.19	2.20
Long-term loans and advances		-	0.00
Other non-current assets	2.8A	2.55	2.55
		8.77	32.44
Current assets			
Current investments		-	-
Inventories	2.9	660.47	505.11
Trade receivables	3.0	1680.42	1499.80
Cash and cash equivalents	3.1	30.49	28.95
Short-term loans and advances	3.2	333.86	417.15
Other current assets	3.3	1.01	32.10
		2706.25	2483.10
TOTAL		2715.04	2515.55

In terms of our attached report of even date

For MADHUSUDAN C MASHRUWALA & CO.
 CHARTERED ACCOUNTANTS
 FRN 105717W

S. V. Mashruwala

SOHAM USHIR MASHRUWALA

(PARTNER)

Mem. No. 137995

UDIN: 24137995 BKCTRP9054

Place : Ahmedabad

Date : 14-11-2024

For SUNREST LIFESCENCE LIMITED

DIN : 07962800

DIN : 07962794

(Managing Director) (Executive Director)

DIN : 09811893

(Independent Director)

Place : Ahmedabad

Date : 14-11-2024

Mehar B. Parekh

Mehar B. Parekh

(CFO)

Avani

DIN : 09608898

(Independent Director)

Place : Ahmedabad

Date : 14-11-2024



SUNREST LIFESCENCE LIMITED

FF-41 AJAY TENAMENT-6 NEAR CANAL NEAR RITANAGAR BUS STAND VASTRAL ROAD Ahmedabad GJ 382415

CIN: U74999GJ2017PLC099606

STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED 30-09-2024

in ₹ Lacs

Particulars	Note	30/09/2024	31/03/2024
Revenue from operations	3.4	1538.92	2948.29
Other income	3.5	0.06	0.10
Total Revenue		1538.98	2948.39
Expenses			
Cost of materials consumed		-	-
Purchases of Stock-in-Trade	3.6	1017.14	2109.04
Changes in inventories of finished goods work-in-progress and Stock-in-Trade	3.7	-155.37	-111.00
Employee benefits expense	3.8	249.11	384.03
Finance costs	3.9	11.69	21.83
Depreciation and amortization expense	4.0	1.22	9.74
Other expenses	4.1	337.78	475.46
Total expenses		1461.57	2889.12
Profit before exceptional, extraordinary and prior period items and tax		77.41	59.27
Exceptional items		-	-
Profit before extraordinary and prior period items and tax		77.41	59.27
Extraordinary Items		-	-
Profit before prior period items and tax		77.41	59.27
Prior Period Items		-	-
Profit before tax		77.41	59.27
Tax expense:	4.2		
Current tax		19.26	37.37
Deferred tax		-0.01	-0.67
Profit/(loss) for the period from continuing operations		58.16	22.57
Profit/(loss) from discontinuing operations		-	-
Tax expense of discontinuing operations		-	-
Profit/(loss) from Discontinuing operations (after tax)		-	-
Profit/(loss) for the period		58.16	22.57
Earnings per equity share:	4.3		
Basic		2.71	0.68
Diluted		2.71	0.68

In terms of our attached report of even date

For SUNREST LIFESCENCE LIMITED

For MADHUSUDAN C MASHRUWALA & CO.

CHARTERED ACCOUNTANTS

FRN : 0105717W

S. H. Mashruwala

SOHAM USHIR MASHRUWALA

(PARTNER)

Mem. No. 137995

UDIN: 24137995BKCI RP9054

DIN : 07962800

(Managing
Director)

DIN : 09811893

(Independent
Director)

Place AHMEDABAD

Date 14-11-2024

2/11/24

DIN : 07962794

(Executive Director)

Meher B. Parvati

(CFO)

Avani

DIN : 09608898

(Independent
Director)

Place : AHMEDABAD

Date : 14-11-2024



Cash Flow Statement of SUNREST LIFESCIENCE LTD.[Formerly Known as Sunrest Lifescience Private Limited]
Annexed to the stand alone balance sheet for the period ended on 30th Sep 2024

Details	Period Ended 30-09-2024	Period Ended 31-03-2024
	Amount in ₹ Lacs	Amount in ₹ Lacs
(A) Cash flow from operating activities		
Net Profit before tax and extra ordinary items	77.41	59.27
Adjustment:		
Depreciation	1.22	9.74
Interest paid	11.69	21.83
Loss on sale of Property, plant & equipment	0.04	-
Dividend income		-
Interest income		-
Operating Profit before working capital changes	90.36	90.85
(Increase)/Decrease in inventories	-155.37	-111.00
(Increase)/Decrease in trade receivables	-180.62	-414.10
(Increase)/Decrease in Loans and Advances	83.29	-330.60
(Increase)/Decrease in Non Current Assets	-	-
(Increase)/Decrease in Current Assets	0.35	-0.39
Increase/(Decrease) in Long term liabilities	34.00	-
Increase/(Decrease) in Trade payables	225.58	-482.28
Increase/(Decrease) in current liabilities	-21.28	-123.56
Increase/(Decrease) in Provisions	13.63	-25.03
Cash generated from operations	89.96	-1396.11
Taxes paid	-28.07	-83.64
Net cash flow from operating activities	61.89	-1479.75
(B) Cash flow from investing activities		
Purchase of Property, Plant & Equipment	-0.24	-0.71
Purchase of investments		-
Sale of Property, Plant & Equipment	21.00	-
Proceeds from sale of Investments	1.65	-
Interest received		-
Dividend received		-
Net cash flow from investing activities	22.41	-0.71
(C) Cash flow from financing activities		
Share capital received		1084.61
Borrowings received		401.65
Borrowings repaid	-71.06	
Dividend paid,including dividend tax		
Interest paid	-11.69	-21.83
Net cash flow from financing activities	-82.75	1464.43
Net increase/(decrease) in cash & cash equivalents	1.55	-16.04



Cash and cash equivalents at the beginning of the year	28.95	44.99
Cash and cash equivalents at the end of the year	30.49	28.95

Notes:

1. The cash flow statement has been prepared under the Indirect method as set out in the AS-3 issued by the Institute of Chartered Accountants of India.

2. Direct taxes paid are treated as arising from operating activities and are not bifurcated between investing and financing activities.

3. Previous Year figures are regrouped wherever necessary.

As per our report of even date attached herewith

For MADHUSUDAN C MASHRUWALA & CO.

FRN : 0105717W

For SUNREST LIFESCIENCE LIMITED

S. Ushir Mashruwala

SOHAM USHIR MASHRUWALA

(PARTNER)

Mem. No. 137995

UDIN: 24137995BKJRP9054

[Signature]

DIN : 07962800

(Managing Director)

[Signature]

DIN : 07962794

(Executive Director)

[Signature]

(CFO)

[Signature]

DIN : 09811893

(Independent Director)

[Signature]

DIN : 09608898


(Independent Director)

Place : Ahmedabad

Date: 14-11-2024

Place : Ahmedabad

Date: 14-11-2024



Note 1: Company overview and significant accounting policies

1. Company Overview

The Company was incorporated as a private limited Company and subsequently was converted into a limited Company. The Company is domiciled in India & engaged in the business of sale of healthcars products, medicines and cosmetics. The Company gets the goods manufactured and markets the same under its own name.

2. Significant accounting policies

The accounting policies set out below have been applied consistently to the years presented in these financial statements.

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with Indian Generally Accepted Accounting Principles (GAAP) under historical cost convention on the accrual basis of accounting and comply with accounting standards, as prescribed under Section 133 of the Companies Act, 2013, as applicable and the relevant provisions of the Companies Act, 2013. The accounting policies adopted in preparation of the financial statements are consistent with those followed in the previous year.

Current and non-current classification

All assets and liabilities are classified into current and non-current.

Current Assets

An asset is classified as current when it satisfies any of the following criteria:

- a. it is expected to be realized in or is intended for sale or consumption in, the Company's normal operating cycle;
- b. it is held primarily for the purpose of being traded;
- c. it is expected to be realized within 12 Months after the reporting date; or
- d. it is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the reporting date.

Current assets include the current portion of non-current financial assets.

All other assets are classified as non-current.

Current Liabilities

A liability is classified as current when it satisfies any of the following criteria:

- a. it is expected to be settled in the company's normal operating cycle;
- b. it is held primarily for the purpose of being traded;
- c. it is due to be settled within 12 months after the reporting date; or the Company does not have an unconditional right to defer settlement of the liability for at least 12 months after the reporting date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.

Current liabilities include current portion of non-current financial liabilities.

All other liabilities are classified as non-current.

Operating cycle

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash or cash equivalents. Based on the nature of operations and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle being a period of 12 months for the purpose of classification of assets and liabilities as current and non-current.



2.2 Use of estimates

The preparation of financial statements in conformity with GAAP requires management to make judgements, estimates and assumptions that affect the reported balances of assets and liabilities, the disclosure of contingent liabilities as at the date of the financial 'Statements and reported- amounts of income and expenses during the reporting period. Actual results could differ from those estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Any revision to accounting estimates is recognized prospectively in current and future periods.

2.3 Revenue recognition

Sale of goods

Revenue from sale of goods is recognized when all the significant risks and rewards of ownership of the goods have been passed to the buyer, usually on delivery of the goods. The company collects GST on behalf of the government and, therefore, these are not economic benefits flowing to the company. Hence, they are excluded from revenue.

2.4 Fixed assets and depreciation

Property, plant and equipment ("PPE")

Property, plant and equipment, capital work in progress are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. The cost comprises purchase price, borrowing costs if capitalization criteria are met, directly attributable cost of bringing the asset to its working condition for the intended use and initial estimate of decommissioning, restoring and similar liabilities. Any trade discounts and rebates are deducted in arriving at the purchase price. Such cost includes the cost of replacing part of the plant and equipment. When significant parts of plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives. Likewise, when a major inspection is performed, its cost is recognised in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognised in profit or loss as incurred.

Gains or losses arising from derecognition of property, plant and equipment are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit and loss when the asset is derecognized.

Depreciation

For depreciation the Company adopts the useful life as prescribed under the Companies Act 2013 and depreciation is calculated as per the written down value method by taking into consideration the useful life and residual value of the asset specified in Part 'C' of Schedule II to the Act.

2.5 Borrowing costs

Borrowing costs are interest and other costs (including exchange differences arising from foreign currency borrowings to the extent that they are regarded as an adjustment to interest costs) incurred by the Company in connection with the borrowing of funds. Borrowing costs directly attributable to acquisition or construction of those PPE which necessarily take a substantial period of time to get ready for their intended use are capitalized. Other borrowing costs are recognized as an expense in the period in which they are incurred.



2.6 Impairment of assets

The carrying values of assets are reviewed at each reporting date to determine if there is indication of any impairment. If any indication exists, the asset's recoverable amount is estimated. The recoverable amount of an asset or smallest group of assets (Cash Generating Units (CGU)) that generates cash inflows from continuing use is the greater of its value in use and its net selling price. In assessing value in use, the estimated future cash flows are discounted to their present value using a post-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the assets or Cash Generating Units (CGU). For assets that are not yet available for use, the recoverable amount is estimated at each reporting date. An impairment loss is recognized whenever the carrying amount of an asset or its cash generating unit exceeds its recoverable amount. Impairment losses are recognized in the statement of profit and loss. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined net of depreciation or amortization, if no impairment loss had been recognized.

2.7 Investment



Investments that are readily realizable and intended to be held for not more than a year from the date of acquisition are classified as current investments. All other investments are classified as non-current investments. However, that part of non-current investments which is expected to be realized within 12 months after the reporting date is also presented under 'current assets' as "current portion of non-current investments" in consonance with the current—non-current classification scheme. Non-current investments (including current portion thereof) are carried at cost less any other-than-temporary diminution in value, determined separately for each individual investment. Current investments are carried at the lower of cost and fair value. The comparison of cost and fair value is done separately in respect of each category of investments. Any reductions in the carrying amount and any reversals of such reductions are charged or credited to the statement of profit and loss.

2.8 Provisions

A provision is recognized if, as a result of a past event, the Company has a present obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are recognized at the best estimate of the expenditure required to settle the present obligation at the balance sheet date. The provisions are measured on an undiscounted basis.

2.9 Inventories

Traded goods are valued at lower of cost and net realizable value. Cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition. Cost is determined on a weighted average basis. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and estimated costs necessary to make the sale.



2.10 Contingent liabilities and contingent assets

A contingent liability exists when there is a possible but not probable obligation, or a present obligation that may but probably will not, require an outflow of resources, or a present obligation whose amount cannot be estimated reliably. Contingent liabilities do not warrant provisions, but are disclosed unless the possibility of outflow of resources is remote. Contingent assets are neither recognized nor disclosed in the financial statements. However, contingent assets are assessed continually and if it is virtually certain that an inflow of economic benefits will arise, the asset and related income are recognized in the period in which the change occurs.

2.11 Taxation

Income-tax expense comprises current tax (i.e. amount of tax for the period', determined in accordance with the income tax law) and deferred tax charge or credit (reflecting the tax effects of timing differences between accounting income and taxable income for the period). The deferred tax charge or credit and the corresponding deferred tax liabilities and assets are recognized using the tax rates that have been enacted or substantively enacted by the balance sheet date. Deferred tax assets are recognized only to the extent there is reasonable certainty that the assets can be realized in future. However, where there is unabsorbed or carried forward losses under taxation laws, deferred tax assets are recognized only if there is a virtual certainty of realization of such assets. Deferred tax assets are reviewed as at each balance sheet date and are written down or written-up to reflect the amount that is reasonably or virtually certain (as the case may be) to be realized.


2.12 Earnings per share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders (after deducting' preference dividends, if any, and attributable taxes) by the weighted average number of equity shares outstanding during the period, Partly paid equity shares are treated as a fraction of an equity share to the extent that they are entitled to participate in dividends relative to a fully paid equity share during the reporting period. The weighted average number of equity shares outstanding during the period is adjusted for events such as bonus issue, bonus element in a rights issue, buy back, share split, and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without a corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

2.13 Cash flow Statement

In the cash flow statement, cash and cash an equivalent includes cash in hand, demand deposits with banks, other short-term highly liquid investments with original maturities of three months or less.



NOTES ON ACCOUNTS FOR THE PERIOD ENDED ON 30-09-2024

2.1 Share Capital

in ₹ Lacs

Particulars	30-09-2024		31/03/2024	
Authorised				
1,40,00,000 (1,40,00,000) Equity Shares of ₹ 10/- Par Value		1400.00		1400.00
		1400.00		1400.00
Issued				
42,91,200 (30,00,000) Equity Shares of ₹ 10/- Par Value		429.12		429.12
		429.12		429.12
Subscribed				
42,91,200 (30,00,000) Equity Shares of ₹ 10/- Par Value		429.12		429.12
		429.12		429.12
Paidup				
42,91,200 (30,00,000) Equity Shares of ₹ 10/- Par Value		429.12		429.12
		429.12		429.12

Rights, preferences and restrictions attached to equity shares

The Company has only one class of equity shares having par value of INR 10 per share. Accordingly, all equity shares rank equally with regard to dividends and share in the Company's residual assets. The equity shares are entitled to receive dividend as declared from time to time after to payment of dividend to preference shareholders. The voting rights of an equity shareholder on a poll (not on show of hands) are in proportion to its share of the paid-up equity capital of the Company. On winding up of the Company, the holders of equity shares will be entitled to receive the residual assets of the Company, remaining after distribution of all preferential amounts in proportion to the number of equity shares held.

Reconciliation

Particulars	30/09/2024		31/03/2024	
	Number of Share	Amount	Number of Share	Amount
Number of shares at the beginning	42,91,200	429.12	30,00,000	300.00
Add : Issued during the period *(refer note below)		-	12,91,200	129.12
Add : Issued during the period # (refer note below)		-		
Less : Bought Back	-	-	-	-
Others	-	-	-	-
Number of shares at the end	42,91,200	429.12	42,91,200	429.12

Details of shares issued for consideration other than cash:-

Note 1: During the financial year 2022-2023, the Company had issued bonus shares without any consideration by capitalizing its reserves during the year. The Company has allotted 9,90,000 equity shares of ₹ 10 each fully paid up by way of bonus shares to the existing share-holders in the ratio of 99:1 i.e. 99 shares for each 1 equity share fully paid up held by the existing share-holders.



Note 2 : During the financial year 2022-23, the Company had issued bonus shares without any consideration by capitalizing its reserves during the year. The Company has allotted 20,00,000 equity shares of ₹ 10 each fully paid up by way of bonus shares to the existing share-holders in the ratio of 2:1 i.e. 2 shares for each 1 equity share fully paid up held by the existing share-holders.

Holding More Than 5%

Particulars	30/09/2024		31/03/2024	
	Number of Share	% Held	Number of Share	% Held
Amit Thakkar	7,49,000	17.45	7,49,000	17.45
Bharat Thakkar	6,75,000	15.73	6,75,000	15.73
Bhagyesh Parekh	6,75,000	15.73	6,75,000	15.73
Nikhil Thakkar	7,50,000	17.48	7,50,000	17.48

Shares held by promoter at the end of the year /period

Particulars	30/09/2024		31/03/2024	
	Number of Share	% Held	Number of Share	% Held
Amit Thakkar	7,49,000	17.45	7,49,000	17.45
Bharat Thakkar	6,75,000	15.73	6,75,000	15.73
Bhagyesh Parekh	6,75,000	15.73	6,75,000	15.73
Nikhil Thakkar	7,50,000	17.48	7,50,000	17.48



2.2 Reserve and Surplus

in ₹ Lacs

Particulars	30/09/2024	31/03/2024
Securities Premium		
Opening Balance	955.49	-
Add: Addition during the year		955.49
	955.49	955.49
Surplus i.e. balance in the Statement of Profit and Loss Account -Opening	33.93	11.36
Amount Transferred From Statement of P&L	58.16	22.57
Appropriation and Allocation		
Less: Issuance of bonus equity shares without any consideration	-	-
	92.09	33.93
	1047.58	989.42

2.3 Long Term Borrowings

in ₹ Lacs

Particulars	30/09/2024	31/03/2024
Long term maturities of finance lease obligations		
Secured against hypothecation of motor car		
Indian Overseas Bank Car Loan*	-	13.86
Less: Current maturity on long term loan disclosed short term borrowings	-	-13.86
		(0)
Loans & Advances from related parties		
Unsecured		
Loans from Directors & relatives#	322.03	346.18
	322.03	346.18

*Terms and Conditions of Loan from Indian Overseas Bank Limited

The loan from Indian Overseas Bank Limited is for the motor vehicle in the name of the Director and carries rate of interest of 7.30% pa. The loan is repayable in 36 monthly installments of INR 121577 each starting from 10th March 2022. The motor vehicle and loan are both in the name of the Director

Terms and conditions of loan from Directors & relatives

The loan from the directors and relatives are interest free and there is no predecided maturity for re-payment.

2.3A Other Long term liabilities

in ₹ Lacs

Particulars	30/09/2024	31/03/2024
Security Deposit from Customer	34.00	-
	34.00	-

2.3B Short term borrowings

in ₹ Lacs

Particulars	30/09/2024	31/03/2024
Current maturity of long term borrowing (refer note Note 2.3)	-	13.86
Cash Credit Limit with Axis Bank Limited §	222.89	255.93
	222.89	269.79

§ The CC Limit from Axis Bank Limited is secured against hypothecation of Present & future entire current assets of the company along with Personal Guaranty of Bharat Thakkar, Bhagyesh Parekh, Amit Thakkar, Nikhil Thakkar (Directors) and Carries rate of interest of REPO + 2.90% (Presently 9.40% P.A) Payable monthly sanction limit of INR 3 Crores the moveable assets of the Company and carries a floating rate of interest

2.4 Trade Payables

as at 30-09-2024


in ₹ Lacs

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME	421.88	-	-	-	421.88
(ii) Others	183.27	-	-	-	183.27
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-
Total					605.15

as at 31-03-2024

in ₹ Lacs

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME	30.76	-	-	-	30.76
(ii) Others	348.81	-	-	-	348.81
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-
Total					379.56



2.7 Property, Plant & Equipment
A) Tangible assets
As at 30-09-2024



Particulars	Gross				Depreciation				Net	
	Opening	Addition	Deduction	Closing	Opening	During Period	Deduction	Closing	Closing	Opening
Office Equipments	1.85			1.85	1.18	0.09		1.27	0.58	0.66
Computer & Peripherals	3.95	0.00		3.95	3.52	0.13		3.65	0.30	0.43
Furniture and Fixtures	6.42			6.42	3.57	0.37		3.93	2.48	2.85
Motor Vehicles	40.26		-40.26	-	18.84	0.38	-19.22	0.00	0.00	21.42
Grand Total	52.47	0.00	-40.26	12.22	27.11	0.97	-19.22	8.86	3.36	25.37
Previous	52.42	0.05	-	52.47	17.63	9.48	-	27.11	25.37	34.80

In ₹ Lacs

B. Intangible Assets

Particulars	Gross				Depreciation				Net	
	Opening	Addition	Deduction	Closing	Opening	During Period	Deduction	Closing	Closing	Opening
Trademark	0.95	0.24		1.19	0.26	0.25		0.51	0.68	0.43
Grand Total	0.95	0.24	-	1.19	0.26	0.25	-	0.51	0.68	0.43
Previous	0.29	0.66	-	0.95	-	0.26	-	0.26	0.69	0.29

In ₹ Lacs



2.5 Other Current Liabilities

Particulars	in ₹ Lacs	
	30/09/2024	31/03/2024
Other payables		
Other Current Liabilities		
Payable towards expenses	14.46	0.16
Statutory Dues	2.24	11.63
Other payables	-	-
Advance from Customer/Security Deposit	-	26.19
	16.70	37.98

2.6 Short Term Provisions

Particulars	in ₹ Lacs	
	30/09/2024	31/03/2024
Tax Provision		
Current Tax		
Provision for Income Tax	-2.18	37.37
Others		
Provision for Salary & wages & expenses	39.77	26.13
	37.58	63.50

2.7A Non-Current Investments

Particulars	in ₹ Lacs	
	30/09/2024	31/03/2024
Non Quoted		
Investment in Equity shares		
Nil Equity Shares of Rs. 10 each of Trilend Pharmaceuticals Limited (PY 11000 Nos)	-	1.65
	-	1.65

Additional Disclosure for Investments

Particulars	in ₹ Lacs	
	30/09/2024	31/03/2024
Aggregate value of quoted investments	-	-
Aggregate market value of quoted investments	-	-
Aggregate value of unquoted investments	-	1.65

2.8 Deferred Taxes


Particulars	in ₹ Lacs	
	30/09/2024	31/03/2024
Deferred Tax Assets(Net)		
On Account of difference of depreciation-deferred tax asset	2.19	2.20
On Account of difference of depreciation- deferred tax liability		
	2.19	2.20

2.8A Other non current assets

Particulars	in ₹ Lacs	
	30/09/2024	31/03/2024
Deposits		
Deposit for leasehold premises	2.55	2.55
	2.55	2.55

2.9 Inventories

Particulars	in ₹ Lacs	
	30/09/2024	31/03/2024
Finished Goods held for trading		
	660.47	505.11
	660.47	505.11



3.0 Trade receivables

in ₹ Lacs

Ageing Schedule as at 30-09-2024

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months to 1 year	1-2 years	2-3 years	More than 3 years	
(i)MSME	-	-	-	-	-	-
(ii)Others	1680.42	-	-	-	-	1680.42
(iii) Disputed dues-MSME	-	-	-	-	-	-
(iv) Disputed dues-Others	-	-	-	-	-	-
Total	1680.42	-	-	-	-	1680.42

Ageing Schedule as at 31-03-2024

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months to 1 year	1-2 years	2-3 years	More than 3 years	
(i)MSME	-	-	-	-	-	-
(ii)Others	-	1499.80	-	-	-	1499.80
(iii) Disputed dues-MSME	-	-	-	-	-	-
(iv) Disputed dues-Others	-	-	-	-	-	-
Total	-	1499.80	-	-	-	1499.80

3.1 Cash and cash equivalents

in ₹ Lacs

Particulars	30/09/2024	31/03/2024
Cash in Hand	24.50	21.24
Balances With Banks		
Balance in Bank account held with Nidhi Co Operative Bank	2.73	2.04
Balance in Bank account held with Axis Bank	3.26	5.67
	30.49	28.95

3.2 Short-term loans and advances

in ₹ Lacs

Particulars	30/09/2024	31/03/2024
Others		
Unsecured, considered good		
Advance given to Trilend Pharma. Pvt. Ltd.	23.74	28.35
Advance paid to Hetvi Lifescience Private Limited for purchase of goods	163.46	255.39
Loans and Advances due by Director- Shri Amitkumar Hiralal Thakkar	-	22.00
Loans and Advances CFO- Meha Parekh	5.00	-
Advance for proposed purchase of office	39.00	23.00
Advance paid to SKNRD BIOTECH (S) for purchase of goods	50.00	50.00
Advance paid to Siroya and Co	20.00	-
Balance with Revenue Authority (GST)	15.31	27.17
Other Short term Loans and Advances		
Security Deposits		
NSDL Deposit	10.85	10.85
Others		
Advance for expenses		
Brisk Gains Pvt. Ltd.	-	0.38
LALLUVADIYA ALPESHKUMAR PRAVIN	5.00	-
TRUE VALUE INFRA LINK LLP	1.50	-
	333.86	417.15

3.3 Other current assets



in ₹ Lacs

Particulars	30/09/2024	31/03/2024
Advance Tax/TDS/TCS	-	30.74
Pre-paid insurance	1.01	1.36
	1.01	32.10

3.4 Revenue from operations

in ₹ Lacs

Particulars	30/09/2024	31/03/2024
Sale of Products		
Sales of Traded goods		
Health care products & Cosmetics	1538.92	2948.29
	1538.92	2948.29



3.5 Other income

Particulars	in ₹ Lacs	
	30/09/2024	31/03/2024
Others		
Profit on Car Sale	-	-
Discount/Kasar/Bank charges	0.06	0.10
	-	-
	0.06	0.10

3.6 Purchases of Stock-in-Trade

Particulars	in ₹ Lacs	
	30/09/2024	31/03/2024
Stock in Trade		
Purchase of Health care products & Cosmetics	1017.14	2109.04
	1017.14	2109.04

3.7 Changes in inventories of finished goods, work-in-progress and Stock-in-Trade

Particulars	in ₹ Lacs	
	30/09/2024	31/03/2024
Opening		
Stock in Trade	505.11	394.11
	505.11	394.11
Closing		
Stock in Trade	660.47	505.11
	660.47	505.11
Increase/Decrease		
Stock in Trade	-155.37	-111.00
	-155.37	-111.00

Details of Changes in Inventory

Particulars	in ₹ Lacs	
	30/09/2024	31/03/2024
Stock in Trade		
Closing Stock	-155.37	-111.00
	-155.37	-111.00

3.8 Employee benefits expense

Particulars	in ₹ Lacs	
	30/09/2024	31/03/2024
Salary, Wages & Bonus		
Salaries and Wages	183.59	338.42
Director's remuneration	8.82	21.02
Contribution to Provident Fund & other funds	10.83	20.27
Other Staff related Expenses*	45.87	4.31
	249.11	384.03

*In the figure for period ended 30-09-2024, it includes FSO incentive of Fin Year 2023-24 which was not due worth INR 2070097

3.9 Finance costs

Particulars	in ₹ Lacs	
	30/09/2024	31/03/2024
Interest Expenses		
Interest on Car Loan & others	10.67	6.54
Processing Fees- Bank charges	-	8.42
Interest on taxes	1.02	6.87
	11.69	21.83

4.0 Depreciation and amortisation expense

Particulars	in ₹ Lacs	
	30/09/2024	31/03/2024
Depreciation & Amortisation		
Depreciation Tangible Assets	0.97	9.48
Depreciation Intangible Assets	0.25	0.26
	1.22	9.74



4.1 Other expenses

Particulars	in ₹ Lacs	
	30/09/2024	31/03/2024
Power & Fuel	0.59	1.22
Rent	6.69	12.84
Legal and Professional fees*	11.92	51.81
Telephone Expenses	0.28	0.54
Insurance Expense	1.13	1.71
Repairs Others	0.07	0.77
Rates & Taxes	0.24	0.14
Authorized capital increase expenses	-	-
Freight & forwarding expenses	18.17	39.37
Sales and marketing expenses	-	-
Reimbursement Expense MR	163.18	216.88
Article Item Expense	1.14	5.39
Other expenses		
Tea & Refreshment Expense	0.20	0.29
Tour & Travelling Expense	58.82	50.27
Printing & Stationary Expense	0.45	0.57
Software Maintenance Expense	1.39	52.38
Turnover Discount / SCHEME GIVEN IN SALE	-	1.13
Courier Expense	0.08	0.15
Godown Expense	0.24	0.78
Meeting Expense and sales promotion	8.20	2.43
Social Media Promotion & Advertisement expenses	0.78	13.53
Vehicle Repairing/Petrol/Diesel	0.21	1.96
Commission Expense	59.02	12.24
Office Exp	1.80	1.77
Bar code expenses	-	-
CDSL/NSDL Expenses	3.00	7.30
Loss on sale of Fixed assets	0.04	-
Misc. Expenses	0.14	-
	337.78	475.46

*Payment to auditors included in legal and professional fees

Particulars	in ₹ Lacs	
	30/09/2024	31/03/2024
Towards Statutory Audit	4.00	-
Towards Taxation services	1.00	-
Towards certification services and others	1.00	-


4.2 Tax expense

Particulars	in ₹ Lacs	
	30/09/2024	31/03/2024
Current tax	17.95	37.37
Reversal of excess provision made during the year	-	-
Previous Year income tax written off	1.31	-
Deferred tax	-0.01	-0.67
	19.25	36.70

4.3 Earnings per equity share

Particulars	in ₹ Lacs	
	30/09/2024	31/03/2024
Earnings Per Equity Share		
Basic EPS Before Extra Ordinary Item		
Numerator for basic EPS	58.16	22.57
Weighted average number of shares	21.46	33.23
Nominal value of one equity share	10	10
Basic EPS	2.71	0.68
Diluted EPS Before Extra Ordinary Item		
Numerator for basic EPS	58.16	22.57
Weighted average number of shares	21.46	33.23
Nominal value of one equity share	10	10
Diluted EPS	2.71	0.68

Note for EPS: The EPS of last audited balance sheet is adjusted in terms of the guidance provided under AS-20 issued by ICAI.



5.0 Additional disclosure requirements

Ratios

Ratio	Numerator	Denominator	Numerator	Denominator	Current Period	Previous Period	% Variance	Reason for more than 25% variance
	Current Period	Current Period	Previous Period	Previous Period				
1) Current Ratio	2706.25	882.31	2483.10	750.83	3.07	3.31	(7.25)	NA
2) Debt-Equity Ratio	356.03	1476.70	346.18	1418.54	0.24	0.24	(1.21)	NA
3) Debt Service Coverage ratio	90.36	24.53	90.85	18.36	3.68	4.95	(25.55)	Decline in earnings available for payments
4) Return on Equity	58.16	1447.62	22.57	864.95	0.04	0.03	53.94	Increase in net profit
5) Inventory Turnover Ratio	1538.92	582.79	2948.29	449.61	2.64	6.56	(59.73)	Decline in sales
6) Trade receivable Turnover ratio	1538.92	1590.11	2948.29	1292.75	0.97	2.28	(57.56)	Decline in sales
7) Trade Payables turnover ratio	1017.14	492.35	2109.04	620.70	2.07	3.40	(39.20)	Decline in purchase
8) Net Capital turnover ratio	1538.92	1823.94	2948.29	1732.27	0.84	1.70	(50.43)	Decline in sales
9) Net profit ratio	58.16	1538.92	22.57	2948.29	0.04	0.01	393.60	Decline in Sales
10) Return on Capital Employed	89.10	2019.41	81.11	2032.31	0.04	0.04	10.56	NA
11) Return on investment	There are no returns received on the investments made by the Company in the form of Dividend or any other source and hence, the ratio is not determined							NA

6.0

Additional disclosures

Details of crypto currency or virtual currency

(a) The Company has neither traded nor invested in Crypto currency or Virtual Currency during the for the period year ended 30th Sept 2024 Further, the Company has also not received any deposits or advances from any person for the purpose of trading or investing in Crypto Currency or Virtual Currency.

(b) The Company has not been declared Wilful Defaulter by any bank or financial institution or government or any government authority.

Undisclosed income

(c) During the Period, the Company has not surrendered or disclosed as income any transactions not recorded in the books of accounts in the course of tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).

(d) Relationship with struck off companies


The Company does not have any transactions with the companies struck off under section 248 of the Companies Act, 2013 or section 560 of the Companies Act, 1956 for the financial year ended on 30th Sept 2024

(e) Compliance with numbers of layers of companies

The Company is in compliance with the number of layers of companies in accordance with clause 87 of Section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017 for the financial years ended on 30th Sept 2024

Utilisation of borrowed funds and share premium

During the financial years ended on 30th Sept 2024, the Company has not advanced or loaned or invested funds (either borrowed funds or share premium or kind of funds) to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding (whether recorded in writing or otherwise) that the Intermediary shall:



- i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or
- (f) ii) provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries.

For financial years ended on 30th Sept 2024, the Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

- i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
- ii) provide any guarantee, security, or the like on behalf of the ultimate beneficiaries.
- (g) As informed to us no proceeding have been initiated nor pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act,1988 (45 of 1988) and rules made thereunder.
- (h) The Company does not have any immoveable properties

7.0 Contingent Liabilities

Particulars	in ₹ Lacs	
	30/09/2024	31/03/2024
1) Corporate guarantee given for loan borrowed by Trilend Pharmaceuticals Private Limited	(Refer Note below)	(Refer Note below)
2) Claims against the Company not acknowledged as debt i.e. Income tax demand	1.50	1.50
3) Claims against the Company not acknowledged as debt i.e. Income tax demand	0.04	0.04

Note for contingent liability

The Company has issued an unconditional & irrevocable corporate guarantee for working capital loan being Term Loan & Overdraft facility borrowed by Trilend Pharmaceuticals Private Limited for a sum of INR 37 lakhs. In the event Trilend Pharmaceuticals Private Limited doesn't repay the loan, the Company would be liable to make the payments of loan along with applicable interest and outstanding amount



8.0 Related party transactions

Amount in ₹ Lacs

Disclosure in terms of AS-18

A. Key managerial persons:

- 1) Bhagyesh Parekh, Non Executive Director
- 2) Amit Thakkar, Whole Time Director
- 3) Nikhil Thakkar, Managing Director
- 4) Bharat Thakkar, Executive Director
- 5) Avani Shah, Independent Director
- 6) Alpesh Thakkar, Director
- 7) Juhi Sawajani, Independent Director

B. Entities over which

KMP exercise significant influence:

- 1) Shiv Pharma
- 2) Trilend Pharmaceuticals Private Limited [Ceased w.e.f 30-09-2024]
- 3) Jay Medicines (Proprietor Mr. Alpesh Thakkar)
- 4) JVS Healthcare

C: Relatives of KMP:

- 1) Meha Parekh, Wife of Director
- 2) Palak Parekh, Daughter of Director
- 3) Monika Thakkar, Relative
- 4) Amita Thakkar, Relative
- 5) Sonal Thakkar, Relative
- 6) Nimesh Thakkar, Relative
- 7) Kashyap B Thakkar, Relative

D: Transactions with related parties

Sr. No.	Nature of transaction	Amount as at 30-09-2024	Amount as at 31-03-2024
1)	Unsecured Loan Taken		
	Bhagyesh Parekh	-	34.00
	Amit Thakkar	-	105.00
	Bharat Thakkar	-	162.27
2)	Unsecured Loan repaid		
	Alpesh Thakkar		-
	Amit Thakkar		60.00
	Bharat Thakkar	6.65	83.00
	Bhagyesh Parekh	17.50	-
	Meha Parekh		-
3)	Purchase of goods		
	Trilend Pharmaceuticals Pvt. Ltd.	-	26.63
4)	Salary & remuneration		
	Monikaben Thakkar	2.26	4.33
	Amita Thakkar	4.81	4.42
	Meha Parekh	2.11	4.12
	Palak Parekh	2.41	4.92
	Sonal Nimeshkumar Thakkar	2.41	
	Kashyap Bharatkumar Thakkar	2.41	
5)	Directors remuneration		
	Amit Thakkar	5.88	7.62
	Nikhil Thakkar	3.61	8.42
	Bharat Thakkar	0.66	4.46
6)	Refund of equity shares subscribed		
	Trilend Pharmaceuticals Pvt. Ltd.	1.65	-
7)	Sales of goods		
	Shiv Pharma	-	5.16
	JVS Healthcare	0.60	-
	Jay Medicines	3.63	-
8)	Directors sitting fees		
	Avani Shah	0.12	0.48
	Juhi Sawajani	0.12	0.48
9)	Advance given received back		
	Trilend Pharmaceuticals Pvt. Ltd.	4.61	30.00
10)	Advance Given		
	Meha Parekh	5.00	-



E. Details of closing balance with related parties

Sr. No.	Name of related parties- Receivable/(Payable)	Amount as at	Amount as at
		30/09/2024	31/03/2024
i.	Shiv Pharma	51.20	51.20
ii.	Jay Medicines		-
iii.	Trilend Pharmaceuticals Private Limited [Creditors account]	-	-4.61
iv.	Meha Parekh	-0.35	-0.35
v.	Amit Thakkar	-88.38	-88.38
vi.	Bhagyesh Parekh	-41.50	-59.00
vii.	Bharat Thakkar	-127.48	-134.13
viii.	Nikhil Thakkar	-64.66	-64.66
ix.	Palak Parekh	-0.40	-0.40
x.	Monikaben Thakkar	-0.38	-0.38
xi.	Amitaben Thakkar	-1.00	-0.40
xii.	Trilend Pharmaceuticals Private Limited Advance paid	23.74	28.35
xiii.	Sonal Nimeshkumar Thakkar	-0.40	-
xiv.	Kashyap Bhartkumar Thakkar	-0.40	-
xv.	JVS Healthcare	0.60	-
xvi.	Avani Shah	0.00	0.00
xvii.	Juhi Sejwani	0.00	0.00

9.0

Disclosure of MSME trade payables

Particulars	Amount in Lakhs	Amount in Lakhs
	Amount as at 30-09-2024	Amount as at 31-03-2024
Principal Amount remaining unpaid to supplier at the end of the year	421.88	30.76
Interest due thereon remaining unpaid to the supplier at the end of the year		-
Amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding interest specified under the ACT		-
Amount of Interest accrued and remaining unpaid at the end of the year		-
Amount of further interest remaining due and payable even in the succeeding years		-

10.0

The Company operates in only one business segment which trading of goods of pharmaceuticals majorly and hence the disclosure in terms of AS-17 is not furnished.

11.0

The Company has not made provision for the retirement benefits for the employees as mandated under AS-15

12.0

Share issue expenses:


The share issue expenses have not been disclosed separately in the profit and loss account and the summary of the said expenses is as stated below

in ₹ Lacs

Particulars	Amount as at 30-09-2024	Amount as at 31-03-2024
Software expenses	0.00	50.00
Professional fees	0.00	43.00

13.0

During the year, the Company has raised funds by issuing equity shares through IPO. The Company has issued 12,91,200 equity shares of Rs. 10 each and has raised Rs. 10,84,60,800/- (including securities premium) by way of making a public issue on the EMERGE platform of NSE



14.0

The Company has used the proceeds of the public issue of the equity shares as follows:

in ₹ Lacs

Particulars	Amount as at 30-09-2024	Amount as at 31-03-2024
Payment to suppliers and vendors(with GST)	0.00	653.29
Payment of salaries	0.00	246.57
Payment of Govt. dues & Taxes	0.00	85.51
Payment for software expenses(with GST)	0.00	54.00
Payment for fees of merchant bankers (incl. GST)	0.00	38.34
Other legal and professional fees	0.00	06.89
Total	0.00	1084.61

15.0

The provisions of Corporate social responsibility are not applicable to the Company and hence, the details for the same are not reported

16.0

The Present half yearly financial Statements for the period ended 30th September,2024 have been approved by the Board of Directors on November 14, 2024

17.0

Previous year figures are regrouped wherever necessary.

For MADHUSUDAN C MASHRUWALA & CO.

Chartered Accountants
FRN-105717W

S. U. Mashruwala

SOHAM USHIR MASHRUWALA
(PARTNER)

Mem. No. 137995

UDIN: 24137995BKCI RP9054

For SUNREST LIFESCIENCE LIMITED

[Signature]

DIN :07962800
(Managing Director)

[Signature]

DIN : 07962794
(Executive Director)

Meher B. Parash

(CFO)

[Signature]

DIN : 09811893
(Independent Director)

Avani


DIN : 09608898
(Independent Director)

Place :AHMEDABAD

Date : 14-11-2024

Place :AHMEDABAD

Date : 14-11-2024



SUNREST LIFESCENCE LIMITED
FF-41 AJAY TENAMENT-6 NEAR CANAL NEAR RITANAGAR BUS STAND VASTRAL ROAD Ahmedabad GJ 382415
CIN: U74999GJ2017PLC099606

Statement of Standalone Audited financial Results for the Six months ended on 30-09-2024

in ₹ lakhs except share and equity share data

Sr. No.	Particulars	Half year ended 30-09-2024	Half year ended 31-03-2024	Half year ended 30-09-2023	Half year ended 31-03-2023	Year ended 31-03-2024	Year ended 31-03-2023
		Audited	Audited	Audited	Un-Audited	Audited	Audited
1	Incomes						
	Revenue from operations	1538.92	1700.79	1247.50	1160.72	2948.29	2464.20
	Other income	0.06	0.02	0.07	0.10	0.10	2.85
	Total Income	1538.98	1700.81	1247.58	1160.82	2948.39	2467.05
2	Expenses						
	Purchases of Stock-in-Trade	1017.14	1296.10	812.95	665.51	2109.04	1652.35
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-155.37	45.64	-156.64	-149.93	-111.00	-164.60
	Employee benefits expense	249.11	189.71	194.32	127.69	384.03	320.10
	Finance costs	11.69	20.65	1.18	1.42	21.83	5.91
	Depreciation and amortization expense	1.22	4.91	4.83	6.49	9.74	12.99
	Other expenses	337.78	244.33	231.13	129.63	475.46	365.90
	Total expenses	1461.57	1801.34	1087.77	780.82	2889.12	2192.66
3	Profit before exceptional and prior period items and tax	77.41	-100.53	159.80	380.00	59.27	274.40
4	Exceptional items		0.00	0.00	0.00	0.00	0.00
5	Profit before Tax	77.41	-100.53	159.80	380.00	59.27	274.40
6	Tax expense:						
	Current tax	19.26	75.44	-38.07	86.94	37.37	71.27
	Deferred tax	-0.01	0.00	-0.67	-0.59	-0.67	-1.19
7	Total Tax expense	19.25	75.44	-38.74	86.35	36.70	70.08
8	Profit/(loss) for the period (5-7)	58.16	-175.97	198.54	293.65	22.57	204.31
9	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
10	Tax expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
11	Profit/(loss) from Discontinuing operations (after tax) [9-10]	0.00	0.00	0.00	0.00	0.00	0.00
12	Profit/(loss) for the period	58.16	-175.97	198.54	293.65	22.57	204.31
13	Paid up equity share capital (face value of Rs. 10/- each)	21,45,600	33,22,800	30,00,000	1,00,000	33,22,800	30,00,000
	Earnings per equity share:						
	Basic	2.71	(5.30)	6.62	293.65	0.68	6.81
	Diluted	2.71	(5.30)	6.62	293.65	0.68	6.81

Notes:

- The above results have been prepared as per Generally Accepted Accounting Principles in India, prescribed u/s section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable and in accordance with the recognition and measurement principles laid down in accounting Standard, as applicable, specified in Section 133 of the Companies Act, 2013 read with relevant rules framed thereunder or as specified by the Institute of Chartered Accountants of India, whichever is applicable.
- The above audited Standalone Financial Results of company for the half year ended 30th September, 2024 and year ended 31st March, 2024 were reviewed and recommended by the Audit committee and approved by the Board of Directors, at their respective meeting held on 14.11.2024
- Previous period figures have been re-grouped and re-classified wherever necessary.
- The Company has not adopted the Indian Accounting Standards (IND AS) in terms of Exemption available to the Companies Listed with EMERGE Platform of NSE
- The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earnings per share in accordance with the Accounting Standard 20 & EPS is not annualized
- As the Company's business activity falls within a single primary business segment, the disclosure requirements as per AS 17 "Segment Reporting" are not applicable.
- The Statutory Auditors of the Company have carried out an audit of the above Financial Results of the Company for the half year ended 30th September, 2024 in terms of the Regulation 33 of the SEBI (LODR) Regulations, 2015 and have issued an unmodified Independent Auditor's Report thereon.

For SUNREST LIFESCENCE LIMITED

Date: 14-11-2024
Place: Ahmedabad


Managing Director


CFO

